Replies to post #110022 on Biotech Values

[DewDiligence]

…where is 5-7% of profit relative to "materiality" from the standpoint of an investor contemplating a suit? Is there some ballpark figure folks here have seen?

There is no precise definition; 5% has been mentioned by some securities lawyers as a reasonable boundary.

In this instance, the arithmetic is moot, IMO. I see zero chance of a shareholder suit against Teva succeeding on the basis of dishonest comments about generic Lovenox by Teva’s executives.